Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.95
    -0.41 (-0.49%)
     

  • GOLD FUTURES

    2,335.00
    -7.10 (-0.30%)
     

  • DOW

    38,473.01
    -30.68 (-0.08%)
     

  • Bitcoin GBP

    51,626.50
    -1,759.40 (-3.30%)
     

  • CMC Crypto 200

    1,388.99
    -35.11 (-2.47%)
     

  • NASDAQ Composite

    15,713.66
    +17.02 (+0.11%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

AstraZeneca's Tagrisso to cost $12,750 for a month's supply

Reuters - UK Focus

(Updates detail on comparable drugs, link to Clovis story)

LONDON, Nov 17 (Reuters) - AstraZeneca (NYSE: AZN - news) 's new lung cancer pill Tagrisso, which won early U.S (Other OTC: UBGXF - news) . approval on Friday, will cost $12,750 for a month's supply.

A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral lung cancer therapies, such as Pfizer (NYSE: PFE - news) 's Xalkori and Novartis (LSE: 0QLR.L - news) ' Zykadia.

AstraZeneca has previously said it believes Tagrisso could generate peak sales of $3 billion a year, making it a key product in the group's growing oncology portfolio.

Its prospects received a boost on Monday when a rival drug from Clovis Oncology (Xetra: C6O.DE - news) hit a snag, with U.S. health regulators asking for more data and Clovis reporting lower-than-expected confirmed response rates. (Reporting by Ben Hirschler; editing by Jason Neely)